WinstonWınston
Back
Chemical Works logo

Chemical Works

RICHT.BD
73
Medical - Pharmaceuticals · Healthcare
Price
12880.00 HUF
-50.00 (-0.39%)
Market Cap
2.36T HUF
Exchange
Budapest Stock Exchange
Winston Score
73
Winston is happy
A high-quality business with solid fundamentals.
Data as of Aug 23, 2026 · filings through Mar 31, 2026
How the score breaks down
Quality
Exceptional
Growth
Mixed
Cash Flow
Exceptional
Stability
Strong
Valuation
Strong
Dividends
Exceptional

Share count falling — buybacks

1.7% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 186.0M (2021) → 182.8M (2025)

Winston Score History

The full picture

Richter Gedeon (traded as RICHT on the Budapest Stock Exchange) is a Hungarian pharmaceutical company that makes and sells prescription medicines, over-the-counter drugs, and active pharmaceutical ingredients. Its most important products are in women's health, including contraceptives and hormone therapies, as well as treatments for central nervous system disorders. The company sells to hospitals, pharmacies, and healthcare systems across Europe, the United States, and many emerging markets.

Richter earns money primarily by selling finished drug products and bulk pharmaceutical ingredients to distributors and healthcare providers. It operates mainly in Central and Eastern Europe but has a meaningful presence in Russia, the CIS region, and growing sales in the US through licensing partnerships. Its competitive edge comes from decades of expertise in female healthcare and a vertically integrated supply chain that keeps costs relatively low. The biggest risk the company faces is its significant exposure to Russia and neighboring markets, where geopolitical instability and currency swings can meaningfully hurt revenue.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-1.7% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-4.0% YoY

YoY Growth Rate

Earnings declining

R&D Spend

91.2B HUF/ year

Declining (-8% vs prior year)

9.8% of revenue

Below sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

27.4%ownership

Insiders own a meaningful stake in the company

Cash Position

Cash flow positive

493.7B HUF cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

Chemical Works's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
67.1%
Premium pricing power — 67.1% gross margin
Profit after running costs
Operating Margin
32.3%
Excellent — 32.3% operating margin
Return on the money invested
ROCE
21.3%
Exceptional — 21.3% return on capital

ROIC between 15% and 25%. Every dollar invested in the business earns 15 to 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+5.4%
Slow sales growth (+5.4% YoY)
Profit growth
EPS YoY
-3.9%
Earnings shrinking (-3.9% YoY)

Slight earnings drop. Typical near a cyclical low.

How steady the profit is
EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
131%
Turns 131% of profit into real cash
Spare cash per sale
FCF Margin
28.2%
Converts sales into free cash efficiently (28.2%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.00
Conservative — low debt load (0.00)
Covers its interest
Interest Cover
5.81x
Adequate interest coverage (5.8x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
10.3x
Attractive valuation — P/E 10.3

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

Cheaper or dearer next year
P/E vs Forward
+3.8
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (10.3 → 6.5)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
5.55%
Healthy income — 5.55% yield

Generous yield. Worth checking whether the payout is sustainable.

Dividend record
Dividend Growth
+211.2%
Dividend growing fast (211.2% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial